Cassava Sciences, Inc., a clinical-stage biotechnology company focused on developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, announced that the topline results from ...
Cassava Sciences' Phase 3 trial for Alzheimer's failed to meet primary or secondary endpoints, leading to the discontinuation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback